Some evidence suggests that T790M subclonality, i.e. the presence of EGFR T790M-positive cells in only a subset of tumour cells, might influence the response of NSCLC patients to the third-generation TKI osimertinib9,11. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.